Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting.

Trial Profile

Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Argatroban (Primary) ; Aspirin; Clopidogrel
  • Indications Cerebrovascular disorders; Restenosis; Stent thrombosis
  • Focus Therapeutic Use
  • Acronyms APORIAS
  • Most Recent Events

    • 26 Sep 2012 Actual initiation date changed from Aug 2010 to Sep 2010 as reported by ClinicalTrials.gov.
    • 26 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 20 Aug 2012 Planned number of patients changed from 100 to 140 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top